February 20, 2024 11:49am

LPS (loss-per-share) releases will present challenges to share pricing with outcomes included

They're coming ... 7 coming so far, 6 reporting (CRSP, IONS, SAGE, RARE, BPMC, ALNY)

Intellia Therapeutics (NTLA) on 2/22, Thursday

Regenxbio (RGNX) on 2/27, Tuesday

MiMedx (MDXG), Editas Medicine (EDIT) and Voyager therapeutics (VYGR) on 2/28, Wednesday

BioLife Solutions (BLFS), on 2/29, Thursday

AxoGen (AXGN) on 3/5, Tuesday




Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.


I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.